

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-9.) (Cancelled)

10.) (Currently amended) A method for treating fibromyalgia, the method comprising the step of subcutaneously or intramuscularly administering a therapeutically effective amount of a botulinum toxin to treat a patient with fibromyalgia, the botulinum toxin administering being carried out at a first location which first location is anatomically distinct from and/or anatomically distant from a second location, at which second location the patient has a fibromyalgia pain which is alleviated by the administration of the botulinum toxin at the first location, wherein the first location and the second location are within a same dermatome, thereby treating fibromyalgia.

11. (Original) The method of claim 10, wherein the first location is a peripheral location.

12. (Original) The method of claim 10, wherein the second location is a locus of pain.

13. (Cancelled)

14. (Original) The method of claim 10, wherein the first location is the head or neck of the patient.

15. (Previously presented) The method of claim 10, wherein the botulinum toxin is a botulinum toxin type A, B, C, D, E, F or G.

16. (Previously presented) The method of claim 10, wherein the botulinum toxin is a botulinum toxin type A.

17. (Currently amended) A method for treating fibromyalgia, the method comprising the step of subcutaneously or intramuscularly administering about 15-180 units of a botulinum toxin to treat a patient with fibromyalgia, the botulinum toxin administering being carried out at a first location which first location is anatomically distinct from and/or anatomically distant from a second location, wherein the first location and the second location are within a same dermatome and at which second location the patient has a fibromyalgia pain which is alleviated by the administration of the botulinum toxin at the first location, thereby treating fibromyalgia.

18. (Previously presented) The method of claim 17, wherein the botulinum toxin is a botulinum toxin type A, B, C, D, E, F or G.

19. (Previously presented) The method of claim 17, wherein the botulinum toxin is a botulinum toxin type A.

20. (Currently amended) A method for treating fibromyalgia, the method comprising the step of subcutaneously or intramuscularly administering a therapeutically effective amount of a botulinum toxin to treat a patient with fibromyalgia, the botulinum toxin administering being carried out at a first location which first location is anatomically distinct from and/or anatomically distant from a second location, wherein the first location and the second location are within a same dermatome and at which second location the patient has a tender point which is alleviated by the administration of the botulinum toxin at the first location, thereby treating fibromyalgia.

21. (New) A method for treating fibromyalgia, the method comprising the step of subcutaneously or intramuscularly administering a therapeutically effective

amount of a botulinum toxin type A to treat a patient with fibromyalgia, the botulinum toxin type A administering being carried out at a first location which first location is anatomically distinct from and/or anatomically distant from a second location, at which second location the patient has a fibromyalgia pain which is alleviated by the administration of the botulinum toxin type A at the first location, wherein the first location and the second location are within a same dermatome, thereby treating fibromyalgia.